Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study

Aneel Arjun Ashrani, Michel K. Barsoum, Daniel J. Crusan, Tanya M. Petterson, Kent R Bailey, John A. Heit

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction The independent effect of lipid lowering therapy (LLT) on venous thromboembolism (VTE) risk is uncertain. Objective To test statin and non-statin LLT as potential VTE risk factors. Methods Using Rochester Epidemiology Project resources, we identified all Olmsted County, MN residents with objectively diagnosed incident VTE (cases) over the 13-year period, 1988-2000 (n = 1340), and one to two matched controls (n = 1538). We reviewed their complete medical records for baseline characteristics previously identified as independent VTE risk factors, and for statin and non-statin LLT. Using conditional logistic regression, we tested the overall effect of LLT on VTE risk and also separately explored the role of statin versus that of non-statin LLT, adjusting for other baseline characteristics. Results Among cases and controls, 74 and 111 received statin LLT, and 32 and 50 received non-statin LLT, respectively. Univariately, and after individually controlling for other potential VTE risk factors (i.e., BMI, trauma/fracture, leg paresis, hospitalization for surgery or medical illness, nursing home residence, active cancer, central venous catheter, varicose veins, prior superficial vein thrombosis, diabetes, congestive heart failure, angina/myocardial infarction, stroke, peripheral vascular disease, smoking, anticoagulation), LLT was associated with decreased odds of VTE (unadjusted OR = 0.73; p = 0.03). When considered separately, statin and non-statin LLT were each associated with moderate, non-significant lower odds of VTE. After adjusting for angina/myocardial infarction, each was significantly associated with decreased odds of VTE (OR = 0.63, p < 0.01 and OR = 0.61, p = 0.04, respectively). Conclusions LLT is associated with decreased VTE risk after adjusting for known risk factors.

Original languageEnglish (US)
Pages (from-to)1110-1116
Number of pages7
JournalThrombosis Research
Volume135
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Venous Thromboembolism
Case-Control Studies
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Population
Therapeutics
Myocardial Infarction
Central Venous Catheters
Peripheral Vascular Diseases
Varicose Veins
Paresis
Nursing Homes
Medical Records
Veins
Leg
Epidemiology
Hospitalization
Thrombosis
Heart Failure
Logistic Models

Keywords

  • Epidemiology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Pulmonary Embolism
  • Venous thromboembolism
  • Venous Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study. / Ashrani, Aneel Arjun; Barsoum, Michel K.; Crusan, Daniel J.; Petterson, Tanya M.; Bailey, Kent R; Heit, John A.

In: Thrombosis Research, Vol. 135, No. 6, 01.06.2015, p. 1110-1116.

Research output: Contribution to journalArticle

Ashrani, Aneel Arjun ; Barsoum, Michel K. ; Crusan, Daniel J. ; Petterson, Tanya M. ; Bailey, Kent R ; Heit, John A. / Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study. In: Thrombosis Research. 2015 ; Vol. 135, No. 6. pp. 1110-1116.
@article{67a48d6d31434c1c8a2e3c9f0942081a,
title = "Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study",
abstract = "Introduction The independent effect of lipid lowering therapy (LLT) on venous thromboembolism (VTE) risk is uncertain. Objective To test statin and non-statin LLT as potential VTE risk factors. Methods Using Rochester Epidemiology Project resources, we identified all Olmsted County, MN residents with objectively diagnosed incident VTE (cases) over the 13-year period, 1988-2000 (n = 1340), and one to two matched controls (n = 1538). We reviewed their complete medical records for baseline characteristics previously identified as independent VTE risk factors, and for statin and non-statin LLT. Using conditional logistic regression, we tested the overall effect of LLT on VTE risk and also separately explored the role of statin versus that of non-statin LLT, adjusting for other baseline characteristics. Results Among cases and controls, 74 and 111 received statin LLT, and 32 and 50 received non-statin LLT, respectively. Univariately, and after individually controlling for other potential VTE risk factors (i.e., BMI, trauma/fracture, leg paresis, hospitalization for surgery or medical illness, nursing home residence, active cancer, central venous catheter, varicose veins, prior superficial vein thrombosis, diabetes, congestive heart failure, angina/myocardial infarction, stroke, peripheral vascular disease, smoking, anticoagulation), LLT was associated with decreased odds of VTE (unadjusted OR = 0.73; p = 0.03). When considered separately, statin and non-statin LLT were each associated with moderate, non-significant lower odds of VTE. After adjusting for angina/myocardial infarction, each was significantly associated with decreased odds of VTE (OR = 0.63, p < 0.01 and OR = 0.61, p = 0.04, respectively). Conclusions LLT is associated with decreased VTE risk after adjusting for known risk factors.",
keywords = "Epidemiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Pulmonary Embolism, Venous thromboembolism, Venous Thrombosis",
author = "Ashrani, {Aneel Arjun} and Barsoum, {Michel K.} and Crusan, {Daniel J.} and Petterson, {Tanya M.} and Bailey, {Kent R} and Heit, {John A.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.thromres.2015.04.005",
language = "English (US)",
volume = "135",
pages = "1110--1116",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study

AU - Ashrani, Aneel Arjun

AU - Barsoum, Michel K.

AU - Crusan, Daniel J.

AU - Petterson, Tanya M.

AU - Bailey, Kent R

AU - Heit, John A.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Introduction The independent effect of lipid lowering therapy (LLT) on venous thromboembolism (VTE) risk is uncertain. Objective To test statin and non-statin LLT as potential VTE risk factors. Methods Using Rochester Epidemiology Project resources, we identified all Olmsted County, MN residents with objectively diagnosed incident VTE (cases) over the 13-year period, 1988-2000 (n = 1340), and one to two matched controls (n = 1538). We reviewed their complete medical records for baseline characteristics previously identified as independent VTE risk factors, and for statin and non-statin LLT. Using conditional logistic regression, we tested the overall effect of LLT on VTE risk and also separately explored the role of statin versus that of non-statin LLT, adjusting for other baseline characteristics. Results Among cases and controls, 74 and 111 received statin LLT, and 32 and 50 received non-statin LLT, respectively. Univariately, and after individually controlling for other potential VTE risk factors (i.e., BMI, trauma/fracture, leg paresis, hospitalization for surgery or medical illness, nursing home residence, active cancer, central venous catheter, varicose veins, prior superficial vein thrombosis, diabetes, congestive heart failure, angina/myocardial infarction, stroke, peripheral vascular disease, smoking, anticoagulation), LLT was associated with decreased odds of VTE (unadjusted OR = 0.73; p = 0.03). When considered separately, statin and non-statin LLT were each associated with moderate, non-significant lower odds of VTE. After adjusting for angina/myocardial infarction, each was significantly associated with decreased odds of VTE (OR = 0.63, p < 0.01 and OR = 0.61, p = 0.04, respectively). Conclusions LLT is associated with decreased VTE risk after adjusting for known risk factors.

AB - Introduction The independent effect of lipid lowering therapy (LLT) on venous thromboembolism (VTE) risk is uncertain. Objective To test statin and non-statin LLT as potential VTE risk factors. Methods Using Rochester Epidemiology Project resources, we identified all Olmsted County, MN residents with objectively diagnosed incident VTE (cases) over the 13-year period, 1988-2000 (n = 1340), and one to two matched controls (n = 1538). We reviewed their complete medical records for baseline characteristics previously identified as independent VTE risk factors, and for statin and non-statin LLT. Using conditional logistic regression, we tested the overall effect of LLT on VTE risk and also separately explored the role of statin versus that of non-statin LLT, adjusting for other baseline characteristics. Results Among cases and controls, 74 and 111 received statin LLT, and 32 and 50 received non-statin LLT, respectively. Univariately, and after individually controlling for other potential VTE risk factors (i.e., BMI, trauma/fracture, leg paresis, hospitalization for surgery or medical illness, nursing home residence, active cancer, central venous catheter, varicose veins, prior superficial vein thrombosis, diabetes, congestive heart failure, angina/myocardial infarction, stroke, peripheral vascular disease, smoking, anticoagulation), LLT was associated with decreased odds of VTE (unadjusted OR = 0.73; p = 0.03). When considered separately, statin and non-statin LLT were each associated with moderate, non-significant lower odds of VTE. After adjusting for angina/myocardial infarction, each was significantly associated with decreased odds of VTE (OR = 0.63, p < 0.01 and OR = 0.61, p = 0.04, respectively). Conclusions LLT is associated with decreased VTE risk after adjusting for known risk factors.

KW - Epidemiology

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Hypolipidemic Agents

KW - Pulmonary Embolism

KW - Venous thromboembolism

KW - Venous Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84929501809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929501809&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2015.04.005

DO - 10.1016/j.thromres.2015.04.005

M3 - Article

C2 - 25891841

AN - SCOPUS:84929501809

VL - 135

SP - 1110

EP - 1116

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -